Published in J Am Chem Soc on December 02, 2009
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res (2011) 3.38
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol (2012) 1.43
Structural diversity of triplet repeat RNAs. J Biol Chem (2010) 1.29
Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res (2011) 1.29
In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc Natl Acad Sci U S A (2011) 1.22
From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res (2012) 1.10
Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. J Am Chem Soc (2011) 1.09
Crystal structures of CGG RNA repeats with implications for fragile X-associated tremor ataxia syndrome. Nucleic Acids Res (2011) 1.06
Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chem Biol (2012) 1.05
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
RNA CoSSMos: Characterization of Secondary Structure Motifs--a searchable database of secondary structure motifs in RNA three-dimensional structures. Nucleic Acids Res (2011) 1.01
MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res (2014) 1.00
Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 × 1 nucleotide UU internal loop conformations. Biochemistry (2011) 1.00
NMR spectroscopy and molecular dynamics simulation of r(CCGCUGCGG)₂ reveal a dynamic UU internal loop found in myotonic dystrophy type 1. Biochemistry (2011) 0.95
The bright side of dark matter: lncRNAs in cancer. J Clin Invest (2016) 0.94
Extraordinarily robust polyproline type I peptoid helices generated via the incorporation of α-chiral aromatic N-1-naphthylethyl side chains. J Am Chem Soc (2011) 0.93
Probing a 2-aminobenzimidazole library for binding to RNA internal loops via two-dimensional combinatorial screening. ACS Chem Biol (2012) 0.93
Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res (2014) 0.90
Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance. J Med Chem (2013) 0.90
Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol (2013) 0.88
Molecular recognition of 6'-N-5-hexynoate kanamycin A and RNA 1x1 internal loops containing CA mismatches. Biochemistry (2011) 0.88
Using modularly assembled ligands to bind RNA internal loops separated by different distances. Chembiochem (2011) 0.87
Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Res (2014) 0.85
Pyrrole-imidazole polyamides distinguish between double-helical DNA and RNA. Angew Chem Int Ed Engl (2012) 0.84
Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem Biol (2014) 0.82
Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci U S A (2016) 0.82
Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs. ACS Chem Biol (2016) 0.81
Long Non-Coding RNAs Embedded in the Rb and p53 Pathways. Cancers (Basel) (2013) 0.80
Influencing uptake and localization of aminoglycoside-functionalized peptoids. Mol Biosyst (2011) 0.80
RNA Structures as Mediators of Neurological Diseases and as Drug Targets. Neuron (2015) 0.79
Structure based approaches for targeting non-coding RNAs with small molecules. Curr Opin Struct Biol (2015) 0.79
Cyclization of peptoids by formation of boronate esters. Tetrahedron Lett (2011) 0.77
Small molecules that target the toxic RNA in myotonic dystrophy type 2. ChemMedChem (2014) 0.77
Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10. Nat Commun (2016) 0.76
Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev (2017) 0.75
Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1. Bioorg Med Chem Lett (2016) 0.75
Human MicroRNA targets. PLoS Biol (2004) 34.51
Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl (2001) 19.25
Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 12.74
Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A (2004) 10.35
Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol (1974) 9.37
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science (2001) 7.34
Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 7.10
Collection of small subunit (16S- and 16S-like) ribosomal RNA structures: 1994. Nucleic Acids Res (1994) 6.71
Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J (2000) 6.56
Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science (2000) 5.85
The MC-Fold and MC-Sym pipeline infers RNA structure from sequence data. Nature (2008) 5.67
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. PLoS Biol (2008) 4.40
RNA-mediated neuromuscular disorders. Annu Rev Neurosci (2006) 4.24
Molecular recognition of DNA by small molecules. Bioorg Med Chem (2001) 3.69
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
MiRNAs and cancer. Am J Pathol (2009) 3.42
Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet (2002) 3.34
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature (2000) 2.94
Fragment-based lead discovery. Nat Rev Drug Discov (2004) 2.83
RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature (2008) 2.74
MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA (2007) 2.58
MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem (2004) 2.52
RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Res (2003) 2.34
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci (2005) 2.31
Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA (2000) 2.25
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
Two-dimensional combinatorial screening identifies specific aminoglycoside-RNA internal loop partners. J Am Chem Soc (2008) 1.84
A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem Biol (2007) 1.83
Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem Biol (2009) 1.83
Revolutions in RNA secondary structure prediction. J Mol Biol (2006) 1.74
SAR by MS: discovery of a new class of RNA-binding small molecules for the hepatitis C virus: internal ribosome entry site IIA subdomain. J Med Chem (2005) 1.59
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol (2003) 1.56
Specificity of aminoglycoside antibiotics for the A-site of the decoding region of ribosomal RNA. Chem Biol (1998) 1.52
Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. Chembiochem (2006) 1.51
Enhanced RNA binding of dimerized aminoglycosides. Bioorg Med Chem (1999) 1.37
Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. Bioconjug Chem (2006) 1.35
Using selection to identify and chemical microarray to study the RNA internal loops recognized by 6'-N-acylated kanamycin A. Chembiochem (2007) 1.31
MicroRNAs in diseases and drug response. Curr Opin Pharmacol (2008) 1.23
Two-dimensional combinatorial screening identifies specific 6'-acylated kanamycin A- and 6'-acylated neamine-RNA hairpin interactions. Biochemistry (2008) 1.06
Aminoglycoside (neomycin) preference is for A-form nucleic acids, not just RNA: results from a competition dialysis study. J Am Chem Soc (2003) 1.06
SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J Med Chem (2002) 0.95
Sequence-specific recognition of the major groove of RNA by deoxystreptamine. Biochemistry (2002) 0.86
Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci U S A (2004) 10.35
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet (2006) 4.35
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet (2004) 3.21
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res (2007) 2.95
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Gene expression profile of aging in human muscle. Physiol Genomics (2003) 2.36
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol (2006) 2.02
Structural features of microRNA (miRNA) precursors and their relevance to miRNA biogenesis and small interfering RNA/short hairpin RNA design. J Biol Chem (2004) 2.01
Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol (2004) 2.00
RNA-dominant diseases. Hum Mol Genet (2006) 2.00
Recent advances in developing small molecules targeting RNA. ACS Chem Biol (2012) 1.97
Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol (2007) 1.91
Hybridization-based unquenching of DNA hairpins on au surfaces: prototypical "molecular beacon" biosensors. J Am Chem Soc (2003) 1.88
Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell (2007) 1.87
Two-dimensional combinatorial screening identifies specific aminoglycoside-RNA internal loop partners. J Am Chem Soc (2008) 1.84
A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem Biol (2007) 1.83
Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem Biol (2009) 1.83
Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol (2006) 1.83
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res (2011) 1.77
Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol (2010) 1.73
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc (2008) 1.70
A superfolding Spinach2 reveals the dynamic nature of trinucleotide repeat-containing RNA. Nat Methods (2013) 1.62
Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol (2007) 1.61
Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet (2003) 1.59
Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res (2005) 1.57
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol (2003) 1.56
Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep (2013) 1.56
Structural basis of microRNA length variety. Nucleic Acids Res (2010) 1.56
Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science (2014) 1.54
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet (2010) 1.46
Computational method for reducing variance with Affymetrix microarrays. BMC Bioinformatics (2002) 1.44
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol (2012) 1.43
CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res (2011) 1.42
Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet (2011) 1.37
Tools for glycomics: mapping interactions of carbohydrates in biological systems. Chembiochem (2004) 1.32
Using selection to identify and chemical microarray to study the RNA internal loops recognized by 6'-N-acylated kanamycin A. Chembiochem (2007) 1.31
Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res (2011) 1.29
Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve (2007) 1.23
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing. Proc Natl Acad Sci U S A (2002) 1.21
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet (2010) 1.19
A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem Biol (2012) 1.16
A mannan binding lectin is involved in cell-cell attachment in a toxic strain of Microcystis aeruginosa. Mol Microbiol (2006) 1.16
Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res (2003) 1.14
The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies. Chembiochem (2010) 1.13
Structure-activity relationships through sequencing (StARTS) defines optimal and suboptimal RNA motif targets for small molecules. Angew Chem Int Ed Engl (2010) 1.11
Myotonic syndromes. Curr Opin Neurol (2002) 1.11
Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther (2011) 1.10
From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res (2012) 1.10
RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet (2007) 1.09
Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. J Am Chem Soc (2011) 1.09
If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials (2011) 1.08
Reduced amount of mitochondrial DNA in aged human muscle. J Appl Physiol (1985) (2002) 1.07
Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology (2004) 1.06
Two-dimensional combinatorial screening identifies specific 6'-acylated kanamycin A- and 6'-acylated neamine-RNA hairpin interactions. Biochemistry (2008) 1.06
Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chem Biol (2012) 1.05
Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve (2007) 1.03
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun (2013) 1.01
RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther (2012) 1.00
Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 × 1 nucleotide UU internal loop conformations. Biochemistry (2011) 1.00
Two-dimensional combinatorial screening and the RNA Privileged Space Predictor program efficiently identify aminoglycoside-RNA hairpin loop interactions. Nucleic Acids Res (2009) 1.00
Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem (2012) 0.99